Ajanta Pharma Ltd on Tuesday (December 23) announced that it has entered into an in-licensing agreement with Biocon Ltd for semaglutide, a GLP-1 receptor agonist. In an exchange filing, Ajanta Pharma said Biocon will supply semaglutide to the company for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, the Middle East and Central Asia.
Semaglutide is indicated to improve glycaemic control in adults. The product patent expires in most of these markets in March 2026. Ajanta Pharma said it plans to commercialise the product after receiving regulatory approvals, which are expected in late 2026 or early 2027.
Yogesh Agrawal, Managing Director, Ajanta Pharma Ltd, said, “GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. We are excited to partner with Biocon for semaglutide and take this important therapy to the markets where Ajanta has strong on-ground presence and deep reach. We are confident of building semaglutide into a meaningful and high-growth brand across these countries in the years ahead.”
“This partnership with Ajanta Pharma is a strategic step in expanding the global footprint of Biocon’s GLP-1 portfolio and maximising the value of our scientific investments in complex peptide development,” Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said.
Shares of Ajanta Pharma ended 1.14% in the red in the session on Tuesday. The stock has fallen close to 11% in the year so far. On the other hand, the shares of Biocon ended 0.4% in the green on Tuesday, and has gained 8.7% in the year so far.
Also Read: Bliss GVS Pharma board approves appointment of S.N. Kamath as Managing Director
First Published: Dec 23, 2025 6:35 PM IS
